Cargando…
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361414/ https://www.ncbi.nlm.nih.gov/pubmed/16622454 http://dx.doi.org/10.1038/sj.bjc.6603096 |
| _version_ | 1782153207241244672 |
|---|---|
| author | Pacilio, C Morabito, A Nuzzo, F Gravina, A Labonia, V Landi, G Rossi, E De Maio, E Di Maio, M D'aiuto, G Botti, G Normanno, N Chiodini, P Gallo, C Perrone, F de Matteis, A |
| author_facet | Pacilio, C Morabito, A Nuzzo, F Gravina, A Labonia, V Landi, G Rossi, E De Maio, E Di Maio, M D'aiuto, G Botti, G Normanno, N Chiodini, P Gallo, C Perrone, F de Matteis, A |
| author_sort | Pacilio, C |
| collection | PubMed |
| description | The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel 80 mg m(−2) and epirubicin 75 mg m(−2) (ED). The response rate (72 vs 79%), the progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy. |
| format | Text |
| id | pubmed-2361414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2006 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23614142009-09-10 Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial Pacilio, C Morabito, A Nuzzo, F Gravina, A Labonia, V Landi, G Rossi, E De Maio, E Di Maio, M D'aiuto, G Botti, G Normanno, N Chiodini, P Gallo, C Perrone, F de Matteis, A Br J Cancer Clinical Study The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel 80 mg m(−2) and epirubicin 75 mg m(−2) (ED). The response rate (72 vs 79%), the progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy. Nature Publishing Group 2006-05-08 2006-04-18 /pmc/articles/PMC2361414/ /pubmed/16622454 http://dx.doi.org/10.1038/sj.bjc.6603096 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Clinical Study Pacilio, C Morabito, A Nuzzo, F Gravina, A Labonia, V Landi, G Rossi, E De Maio, E Di Maio, M D'aiuto, G Botti, G Normanno, N Chiodini, P Gallo, C Perrone, F de Matteis, A Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title_full | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title_fullStr | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title_full_unstemmed | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title_short | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial |
| title_sort | is epirubicin effective in first-line chemotherapy of metastatic breast cancer (mbc) after an epirubicin-containing adjuvant treatment? a single centre phase iii trial |
| topic | Clinical Study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361414/ https://www.ncbi.nlm.nih.gov/pubmed/16622454 http://dx.doi.org/10.1038/sj.bjc.6603096 |
| work_keys_str_mv | AT pacilioc isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT morabitoa isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT nuzzof isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT gravinaa isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT laboniav isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT landig isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT rossie isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT demaioe isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT dimaiom isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT daiutog isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT bottig isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT normannon isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT chiodinip isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT galloc isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT perronef isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial AT dematteisa isepirubicineffectiveinfirstlinechemotherapyofmetastaticbreastcancermbcafteranepirubicincontainingadjuvanttreatmentasinglecentrephaseiiitrial |